NAGLAZYME (galsulfase)
METABOLIC DISEASE ENZYME REPLACEMENT - MUCOPOLYSACCHARIDOSIS · MAROTEAUX-LAMY SYNDROME
BIOMARIN PHARMA
Drug class
Mucopolysaccharidosis VI (MPS VI) Treatment Agents
Mucopolysaccharidosis VI (MPS VI) treatment agents constitute a specialized therapeutic category—predominantly represented by enzyme replacement therapies such as recombinant galsulfase—specifically indicated for the management of mucopolysaccharidosis VI, also known as Maroteaux-Lamy syndrome. Read more about Mucopolysaccharidosis VI (MPS VI) Treatment Agents
1 drugs in this class 1 manufacturers
Drugs in Mucopolysaccharidosis VI (MPS VI) Treatment Agents
Filter & compare in the drug finder →
Opens the drug finder with Mucopolysaccharidosis VI (MPS VI) Treatment Agents preselected. Add indication or manufacturer filters there.
Mucopolysaccharidosis VI (MPS VI) treatment agents constitute a specialized therapeutic category—predominantly represented by enzyme replacement therapies such as recombinant galsulfase—specifically indicated for the management of mucopolysaccharidosis VI, also known as Maroteaux-Lamy syndrome.
While formularies and compendia may group these therapies under this disease-specific label, they function pharmacologically as exogenous enzyme substitutes that replace deficient N-acetylgalactosamine 4-sulfatase (arylsulfatase B) activity.
By facilitating cellular uptake and targeting to lysosomes, these agents catabolize accumulated glycosaminoglycans, specifically dermatan sulfate, thereby preventing systemic lysosomal storage buildup and improving patient physical endurance, mobility, and joint function.
-
patsnap.com
Mucopolysaccharidosis VI (MPS VI) treatment agents constitute a specialized therapeutic category—predominantly represented by enzyme replacement therapies such as recombinant galsulfase—specifically indicated for the management of mucopolysaccharidosis VI, also known as Maroteaux-Lamy syndrome While formularies and compendia may group these therapies under this disease-specific label, they function pharmacologically as exogenous enzyme substitutes that replace deficient N-acetylgalactosamine 4-s...
-
goodrx.com
Mucopolysaccharidosis VI (MPS VI) treatment agents constitute a specialized therapeutic category—predominantly represented by enzyme replacement therapies such as recombinant galsulfase—specifically indicated for the management of mucopolysaccharidosis VI, also known as Maroteaux-Lamy syndrome By facilitating cellular uptake and targeting to lysosomes, these agents catabolize accumulated glycosaminoglycans, specifically dermatan sulfate, thereby preventing systemic lysosomal storage buildup and ...
-
fda.gov
Mucopolysaccharidosis VI (MPS VI) treatment agents constitute a specialized therapeutic category—predominantly represented by enzyme replacement therapies such as recombinant galsulfase—specifically indicated for the management of mucopolysaccharidosis VI, also known as Maroteaux-Lamy syndrome By facilitating cellular uptake and targeting to lysosomes, these agents catabolize accumulated glycosaminoglycans, specifically dermatan sulfate, thereby preventing systemic lysosomal storage buildup and ...
-
massgeneralbrighamhealthplan.org
While formularies and compendia may group these therapies under this disease-specific label, they function pharmacologically as exogenous enzyme substitutes that replace deficient N-acetylgalactosamine 4-sulfatase (arylsulfatase B) activity
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.